Drug intelligence / Profile preview

LL-10

Development stage: Unknown
Lead developer: Shandong New Time Pharmaceutical
Modality: Small Molecules
Administration: Subcutaneous, Femoral Nerve Block

Overview

LL-10 is a code name for a pharmaceutical drug, identified as "左布比羟利溴铵注射液" (Levobupivacaine Hydroxylammonium Bromide Injection). It is a combination drug containing Levobupivacaine, a long-acting amide-type local anesthetic, and Hydroxylammonium Bromide. It is currently undergoing a Phase I clinical study to evaluate its safety, tolerance, and pharmacokinetics in healthy volunteers. The drug is being developed by Shangdong New Times Pharmaceutical Co., Ltd. and is administered via subcutaneous injection and femoral nerve block.

Other names: 左布比羟利溴铵注射液Levobupivacaine Hydroxylammonium Bromide Injection

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on LL-10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LL-10.

Explore the full profile